Literature DB >> 28151474

LincRNA-Gm4419 knockdown ameliorates NF-κB/NLRP3 inflammasome-mediated inflammation in diabetic nephropathy.

Hong Yi1,2, Rui Peng3, Lu-Yu Zhang2, Yan Sun1,2, Hui-Min Peng1,4, Han-Deng Liu4, Li-Juan Yu4, Ai-Ling Li1,2, Ya-Juan Zhang1,2, Wen-Hao Jiang1,2, Zheng Zhang1,2.   

Abstract

Diabetic nephropathy (DN) as the primary cause of end-stage kidney disease is a common complication of diabetes. Recent researches have shown the activation of nuclear factor kappa light-chain enhancer of activated B cells (NF-κB) and NACHT, LRR and PYD domain-containing protein 3 (NLRP3) inflammasome are associated with inflammation in the progression of DN, but the exact mechanism is unclear. Long noncoding RNAs (lncRNAs) have roles in the development of many diseases including DN. However, the relationship between lncRNAs and inflammation in DN remains largely unknown. Our previous study has revealed that 14 lncRNAs are abnormally expressed in DN by RNA sequencing and real-time quantitative PCR (qRT-PCR) in the renal tissues of db/db DN mice. In this study, these lncRNAs were verified their expressions by qRT-PCR in mesangial cells (MCs) cultured under high- and low-glucose conditions. Twelve lncRNAs displayed the same expressional tendencies in both renal tissues and MCs. In particular, long intergenic noncoding RNA (lincRNA)-Gm4419 was the only one associating with NF-κB among these 12 lncRNAs by bioinformatics methods. Moreover, Gm4419 knockdown could obviously inhibit the expressions of pro-inflammatory cytokines and renal fibrosis biomarkers, and reduce cell proliferation in MCs under high-glucose condition, whereas overexpression of Gm4419 could increase the inflammation, fibrosis and cell proliferation in MCs under low-glucose condition. Interestingly, our results showed that Gm4419 could activate the NF-κB pathway by directly interacting with p50, the subunit of NF-κB. In addition, we found that p50 could interact with NLRP3 inflammasome in MCs. In conclusion, our findings suggest lincRNA-Gm4419 may participate in the inflammation, fibrosis and proliferation in MCs under high-glucose condition through NF-κB/NLRP3 inflammasome signaling pathway, and may provide new insights into the regulation of Gm4419 during the progression of DN.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28151474      PMCID: PMC5386454          DOI: 10.1038/cddis.2016.451

Source DB:  PubMed          Journal:  Cell Death Dis            Impact factor:   8.469


  69 in total

1.  Human genome: end of the beginning.

Authors:  Lincoln D Stein
Journal:  Nature       Date:  2004-10-21       Impact factor: 49.962

2.  Specific-site methylation of tumour suppressor ANKRD11 in breast cancer.

Authors:  Sue Ping Lim; Nick C Wong; Rachel J Suetani; Kristen Ho; Jane Lee Ng; Paul M Neilsen; Peter G Gill; Raman Kumar; David F Callen
Journal:  Eur J Cancer       Date:  2012-04-24       Impact factor: 9.162

3.  Genome-wide identification of human- and primate-specific core promoter short tandem repeats.

Authors:  A Bushehri; M R Mashhoudi Barez; S K Mansouri; A Biglarian; M Ohadi
Journal:  Gene       Date:  2016-04-22       Impact factor: 3.688

4.  Revisiting inflammation in diabetic nephropathy: the role of the Nlrp3 inflammasome in glomerular resident cells.

Authors:  Norihiko Sakai; Takashi Wada
Journal:  Kidney Int       Date:  2015-01       Impact factor: 10.612

5.  Long non-coding RNA LINC01133 inhibits epithelial-mesenchymal transition and metastasis in colorectal cancer by interacting with SRSF6.

Authors:  Jianlu Kong; Wenjie Sun; Chen Li; Ledong Wan; Shuo Wang; Yihua Wu; Enping Xu; Honghe Zhang; Maode Lai
Journal:  Cancer Lett       Date:  2016-07-18       Impact factor: 8.679

6.  Regulation of DEK expression by AP-2α and methylation level of DEK promoter in hepatocellular carcinoma.

Authors:  Ming-Xu Qiao; Chun Li; Ai-Qun Zhang; Ling-Ling Hou; Juan Yang; Hong-Gang Hu
Journal:  Oncol Rep       Date:  2016-07-28       Impact factor: 3.906

7.  BAY 11-7082 ameliorates diabetic nephropathy by attenuating hyperglycemia-mediated oxidative stress and renal inflammation via NF-κB pathway.

Authors:  Sambasiva Rao Kolati; Eshvendar Reddy Kasala; Lakshmi Narendra Bodduluru; Jalandhar Reddy Mahareddy; Shravan Kumar Uppulapu; Ranadeep Gogoi; Chandana C Barua; Mangala Lahkar
Journal:  Environ Toxicol Pharmacol       Date:  2015-02-07       Impact factor: 4.860

8.  miR-451 suppresses the NF-kappaB-mediated proinflammatory molecules expression through inhibiting LMP7 in diabetic nephropathy.

Authors:  Yan Sun; Rui Peng; Huimin Peng; Handeng Liu; Li Wen; Tianhui Wu; Hong Yi; Ailing Li; Zheng Zhang
Journal:  Mol Cell Endocrinol       Date:  2016-06-03       Impact factor: 4.102

9.  NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model.

Authors:  Beibei Luo; Bo Li; Wenke Wang; Xiangjuan Liu; Yanfei Xia; Cheng Zhang; Mingxiang Zhang; Yun Zhang; Fengshuang An
Journal:  PLoS One       Date:  2014-08-19       Impact factor: 3.240

10.  JASPAR 2016: a major expansion and update of the open-access database of transcription factor binding profiles.

Authors:  Anthony Mathelier; Oriol Fornes; David J Arenillas; Chih-Yu Chen; Grégoire Denay; Jessica Lee; Wenqiang Shi; Casper Shyr; Ge Tan; Rebecca Worsley-Hunt; Allen W Zhang; François Parcy; Boris Lenhard; Albin Sandelin; Wyeth W Wasserman
Journal:  Nucleic Acids Res       Date:  2015-11-03       Impact factor: 16.971

View more
  74 in total

Review 1.  Epigenetic Risk Profile of Diabetic Kidney Disease in High-Risk Populations.

Authors:  Lixia Xu; Rama Natarajan; Zhen Chen
Journal:  Curr Diab Rep       Date:  2019-02-07       Impact factor: 4.810

2.  Pioglitazone ameliorates retinal ischemia/reperfusion injury via suppressing NLRP3 inflammasome activities.

Authors:  Yue-Lu Zhang; Ruo-Bing Wang; Wei-Yi Li; Fang-Zhou Xia; Lin Liu
Journal:  Int J Ophthalmol       Date:  2017-12-18       Impact factor: 1.779

3.  Downregulation of DAPK1 promotes the stemness of cancer stem cells and EMT process by activating ZEB1 in colorectal cancer.

Authors:  Wenzheng Yuan; Jintong Ji; Yan Shu; Jinhuang Chen; Sanguang Liu; Liang Wu; Zili Zhou; Zhengyi Liu; Qiang Tang; Xudan Zhang; Xiaogang Shu
Journal:  J Mol Med (Berl)       Date:  2018-11-20       Impact factor: 4.599

4.  Dysregulated expression but redundant function of the long non-coding RNA HOTAIR in diabetic kidney disease.

Authors:  Syamantak Majumder; Mitchell J Hadden; Karina Thieme; Sri N Batchu; Divya Niveditha; Shibasish Chowdhury; Veera Ganesh Yerra; Suzanne L Advani; Bridgit B Bowskill; Youan Liu; Hana Vakili; Tamadher A Alghamdi; Kathryn E White; Laurette Geldenhuys; Ferhan S Siddiqi; Andrew Advani
Journal:  Diabetologia       Date:  2019-08-09       Impact factor: 10.122

Review 5.  Long Noncoding RNAs in Diabetes and Diabetic Complications.

Authors:  Amy Leung; Rama Natarajan
Journal:  Antioxid Redox Signal       Date:  2017-10-30       Impact factor: 8.401

6.  Transcriptome expression profiles associated with diabetic nephropathy development.

Authors:  Jing Jing; Liyuan Song; Dan Zuo; Wenyang Li; Yujing Sun; Xiaoli Ma; Jianmin Ren
Journal:  Mol Cell Biochem       Date:  2022-03-31       Impact factor: 3.396

Review 7.  Linking diabetic vascular complications with LncRNAs.

Authors:  Amy Leung; Vishnu Amaram; Rama Natarajan
Journal:  Vascul Pharmacol       Date:  2018-02-03       Impact factor: 5.773

8.  The role of the LncRNA-FA2H-2-MLKL pathway in atherosclerosis by regulation of autophagy flux and inflammation through mTOR-dependent signaling.

Authors:  Feng-Xia Guo; Qian Wu; Pan Li; Lei Zheng; Shu Ye; Xiao-Yan Dai; Chun-Min Kang; Jing-Bo Lu; Bang-Ming Xu; Yuan-Jun Xu; Lei Xiao; Zhi-Feng Lu; Huan-Lan Bai; Yan-Wei Hu; Qian Wang
Journal:  Cell Death Differ       Date:  2019-01-25       Impact factor: 15.828

Review 9.  Lnc-ing non-coding RNAs with metabolism and diabetes: roles of lncRNAs.

Authors:  Neha Goyal; Devesh Kesharwani; Malabika Datta
Journal:  Cell Mol Life Sci       Date:  2018-01-31       Impact factor: 9.261

Review 10.  Interactions among Long Non-Coding RNAs and microRNAs Influence Disease Phenotype in Diabetes and Diabetic Kidney Disease.

Authors:  Swayam Prakash Srivastava; Julie E Goodwin; Pratima Tripathi; Keizo Kanasaki; Daisuke Koya
Journal:  Int J Mol Sci       Date:  2021-06-02       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.